Myriad Genetics

What Myriad Genetics does

Myriad Genetics (NASDAQ: MYGN), founded in 1991 and headquartered in Salt Lake City, Utah, is a publicly traded molecular diagnostics company that discovers, develops, and commercializes genetic tests across three business segments: Oncology, Reproductive Health, and Psychiatric Genomics. The company serves a distributed base of U.S. healthcare providers — oncologists, OB/GYNs, urologists, primary care physicians, and psychiatrists — through an enterprise field sales organization supplemented by direct-to-consumer ordering options and EMR integrations with Epic Aura, Flatiron OncoEMR, athena, eClinicalWorks, and NextGen-Office.

The core technology platform combines next-generation sequencing, whole-genome sequencing, and circulating tumor DNA analysis to deliver an extensive test catalog: MyRisk (63-gene hereditary cancer panel with RiskScore), BRACAnalysis CDx and MyChoice CDx (FDA-approved companion diagnostics), Precise Tumor (500+ gene profiling), Precise MRD (ultrasensitive ctDNA monitoring at 1.45 ppm LOD), Prolaris + AI (genomics plus PATHOMIQ digital pathology), GeneSight (pharmacogenomics), and the reproductive health suite (Prequel, Foresight, FirstGene, SneakPeek). Patent portfolio spans BRCA1/2, newly granted MRD IP, and recent EU Unified Patent Court wins.

Revenue is generated on a per-test basis, with most tests covered by commercial and federally funded insurance and a Myriad Financial Assistance Program covering 58% of eligible patients. The company reported FY2025 revenue of $824.5M with FY2026 guidance of $860-880M. Distribution mixes direct U.S. field sales with international channel partnerships (Zydus Lifesciences for India) and biopharma companion diagnostic collaborations.

Name

Myriad Genetics

Legal name

Myriad Genetics, Inc.

Website

https://myriad.com

Company type

Public

Founded year

1991

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Myriad Genetics is a publicly traded molecular diagnostics company developing genetic tests across oncology, reproductive health, and psychiatric genomics, serving oncologists, OB/GYNs, urologists, PCPs, and psychiatrists via an enterprise field sales model and EMR-integrated ordering.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Population Genomics & Preventive Precision Health Programs (HLAAANAL), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Molecular diagnostics
• Hereditary cancer testing
• Prenatal genetic screening
• Companion diagnostics
• Pharmacogenomic testing

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Hereditary Cancer Testing: Core testing franchise delivering hereditary cancer risk assessment across 63 genes and 11 cancer types, including MyRisk and BRACAnalysis CDx tests. Volume-driven with 14% volume growth in hereditary cancer testing reported in Q1 2026.
2. Reproductive Health Testing: Prenatal screening (Prequel, FirstGene) and carrier screening (Foresight) products generating revenue per test. Facing headwinds with prenatal revenue declining 15% year-over-year.
3. Psychiatric Genomics / GeneSight: Pharmacogenomic mental health test generating revenue per test, with 24% revenue growth in Q1 2026. Faces reimbursement headwinds from UnitedHealthcare coverage discontinuation.
4. Precise MRD / Oncology: Molecular residual disease testing and tumor genomic profiling (Precise Tumor, MyChoice CDx, Prolaris) representing the company's growth driver, with breast cancer MRD launched commercially in March 2026.
5. Credit Facilities / Financing: $200 million credit facility secured with OrbiMed (healthcare investment firm) including $125 million funded capital and an option for additional $75 million, replacing prior financing arrangement.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels11 records

Core offering

Myriad Genetics is a molecular diagnostics company that develops and commercializes genetic and genomic tests across oncology, reproductive health, urology, and mental health. The company analyzes patient DNA samples in its laboratories and delivers clinical reports that inform hereditary cancer risk, tumor profiling, companion diagnostic selection, molecular residual disease (MRD) monitoring, pharmacogenomic drug response, and prenatal screening. Its products are ordered predominantly by healthcare providers and reimbursed through insurance or paid for via direct-to-consumer channels.

Product overview

Myriad Genetics operates a multi-segment molecular diagnostics and precision medicine platform with four core product categories: Oncology (Precise MRD, MyRisk, MyChoice CDx, BRACAnalysis CDx, Precise Tumor, Prolaris + AI, FOLR1/FRA), Reproductive Health (Foresight, Prequel, FirstGene, SneakPeek), Mental Health (GeneSight), and Urology (Prolaris + AI, MyRisk). The portfolio spans hereditary cancer risk assessment, tumor genomic profiling, molecular residual disease monitoring, carrier screening, prenatal screening, and pharmacogenomics, offering both standalone tests and integrated workflow solutions. EMR integrations with Epic, Flatiron Health OncoEMR, athena, eCW, and NextGen-Office enable streamlined ordering and consolidated results reporting.

Differentiator

Problem solved

Functional benefit

Brands

• MyRisk: Hereditary cancer risk test evaluating 63 genes associated with 11 hereditary cancers, includes RiskScore for breast cancer risk assessment
• Prolaris
• GeneSight
• Prequel
• Foresight
• MyChoice CDx
• Precise Tumor
• Precise MRD
• BRACAnalysis CDx
• SneakPeek
• FirstGene

Products and services

• MyRisk Hereditary Cancer Test

Quantifiable outcome

• Precise MRD achieved 100% specificity in predicting complete treatment response in breast cancer patients (MONITOR-Breast study)
• +6 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability8 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• CelLBxHealthminorGTM or Marketing Partner · 23 June 2026CelLBxHealth's Parsortix platform pivoting toward partnership-led commercialization with validated early collaborations including Myriad Genetics, AstraZeneca, AdventHealth, and Royal Marsden. Cavendish analyst note identifies Myriad as a validated collaboration partner in CelLBxHealth's commercial strategy.
• PATHOMIQ AIcoreTechnology or Integration · 26 May 2026Myriad developed Prolaris + AI, the first prostate cancer biomarker test combining clinical-pathological features, a molecular score, and AI-powered digital pathology technology through partnership with PATHOMIQ AI. The AI-GUR score predicts Gleason score upgrade at follow-up biopsy and is validated in a study of 1,294 patients.
• QIAGENminorStrategic or Co-development Partner · 16 April 2026QIAGEN and Myriad Genetics developed new QIAseq research panels for homologous recombination deficiency (HRD) research, designed for use with Element Biosciences' AVITI platform. QIAGEN introduced the QIAGEN Discovery Platform, an AI-grounding solution for drug discovery research, showcasing the partnership at AACR 2026.
• Clairity and MagViewminorStrategic or Co-development Partner · 5 February 2026Strategic collaboration to integrate AI-powered breast cancer risk assessment tools with Myriad's existing hereditary cancer testing platform, enhancing comprehensive breast cancer risk assessment capabilities in the U.S. market.
• Zydus LifesciencescoreChannel Partner/ Reseller/ Distributor · 22 December 2025Zydus Lifesciences signed an agreement to exclusively commercialize three Myriad Genetics cancer tests (BRACAnalysis, MyRisk, MyChoice) in India. This partnership expands Myriad's geographic footprint in one of the world's largest pharmaceutical markets and represents a key international growth initiative.
• EpiccoreTechnology or Integration · 1 October 2024Myriad offers native bidirectional EMR integration with Epic through the Epic Aura founding member network. Epic-certified analysts guide adoption, and Myriad provides Variant-Level Data for Epic Genomics and VCF data for research needs.
• Intermountain Precision Genomics (IPG)coreStrategic or Co-development Partner · 1 February 2024Myriad Genetics acquired assets from Intermountain Precision Genomics in February 2024, strengthening its portfolio with IPG's tumor and liquid biopsy testing services and CLIA-certified laboratory in Utah. This acquisition enhances Myriad's tumor-profiling and precision oncology testing capabilities.
• Flatiron Health (OncoEMR)coreTechnology or Integration · 1 January 2024Myriad partnered with Flatiron Health to provide integration to OncoEMR for streamlined end-to-end workflow for germline testing. Clinicians have access to results at point-of-care, facilitating personalized treatment decisions while reducing administrative burden.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Natera: Natera is a direct competitor across reproductive health (Panorama NIPT, Vistara carrier/PRS), hereditary cancer (Empower genetics), and most importantly Signatera tumor-informed MRD — the primary head-to-head competitor to Myriad's Precise MRD.
• Guardant Health: Guardant competes directly with Precise Tumor (Guardant360 CDx), Precise MRD (Guardant Reveal), and offers Shield for CRC screening — overlapping in liquid biopsy, comprehensive genomic profiling, and MRD monitoring with similar biopharma and provider channels.
• Veracyte: Veracyte is a genomic diagnostics competitor across urologic oncology (Decipher Prostate, closely comparable to Prolaris + AI), Afirma thyroid, and HRD/MRD initiatives; it has also hired away Myriad's former CTO, making it a strategic technology and talent competitor.
• NeoGenomics: NeoGenomics is a direct peer in oncology testing services, offering comprehensive tumor profiling (RaDaR MRD), hereditary cancer, and pharma/CDx services with overlapping oncologist and biopharma customers across the U.S.
• Exact Sciences: Exact Sciences operates an integrated molecular diagnostics platform (Cologuard, Oncotype DX, Riskguard hereditary cancer, OncoExTra tumor profiling) overlapping directly with Myriad's hereditary cancer, oncology, and risk-assessment franchises.
• Tempus AI: Tempus AI offers NGS tumor profiling, MRD (xF), hereditary testing, and an AI/data platform that mirrors Myriad's emerging AI-diagnostic strategy; it competes for biopharma companion diagnostic and trial-enrichment partnerships.
• Caris Life Sciences: Caris offers MI Profile (comprehensive tumor profiling), MI Cancer Seek (multi-cancer screening with FDA breakthrough designation), and Caris Assure MRD — directly overlapping with Precise Tumor, Precise MRD, and biopharma CDx offerings.

Broad incumbents

• Foundation Medicine (Roche): Foundation Medicine's FoundationOne CDx and FoundationOne Liquid CDx are entrenched comprehensive tumor profiling and CDx products across oncology indications, broadly overlapping with Precise Tumor and MyChoice CDx within pharma and academic oncology.

Emerging players

• Invitae: Invitae competes in hereditary cancer, reproductive health (carrier/NIPT via Prelude), and pharmacogenomics — overlapping substantially with Myriad's genetic testing franchises though currently in financial restructuring, weakening competitive intensity in the near term.
• SOPHiA GENETICS: SOPHiA GENETICS is both a Myriad partner (biomarker validation, CDx development) and a competitor in AI-powered genomics analytics and hereditary/oncology NGS testing across European and global hospital systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/myriadgenetics
• YouTubeyoutube.com/user/MyriadGenetics/videos
• Facebookfacebook.com/MyriadGenetics
• LinkedInlinkedin.com/company/myriad-genetics
• Instagraminstagram.com/myriadgenetics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myriad Genetics